Loading
A phase 2 trial in colorectal cancer, run by Oncology Institute of Southern Switzerland, now recruiting.
Metronidazole as Preoperative Therapy in CRC / FusoMetro-001 is a phase 2, interventional study registered as NCT05748145 by Oncology Institute of Southern Switzerland, with a registry enrolment figure of 40 participants, started 2023-09-11 and due to reach its primary completion in 2026-12-31. Interventions recorded: Metronidazole Oral. Conditions listed: Colorectal Cancer. Primary outcome: Impact of metronidazole on F.n. loads in CRC tissues.. Colorectal eligibility wording from the registry: "* Untreated, primary colorectal adenocarcinoma (\> 15 cm from the anal verge)". Sites: Switzerland. No results are recorded here; the registry entry is the source.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.